Riboflavin

Riboflavin

SCHEMBL232228

CCCC(=O)O.Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.84
KMT2A Q03164 7/20 0.84
USP2 O75604 4/20 0.84
KDM4E B2RXH2 4/20 0.84
HAT1 O14929 4/20 0.84
RBBP7 Q16576 4/20 0.84
HTT P42858 4/20 0.84
RECQL P46063 3/20 0.84
CASP7 P55210 3/20 0.84
MAPT P10636 3/20 0.84
CASP1 P29466 2/20 0.84
BRCA1 P38398 2/20 0.84
HSD17B10 Q99714 2/20 0.84
TST Q16762 2/20 0.84
TDP1 Q9NUW8 2/20 0.84
ALDH1A1 P00352 2/20 0.84
LMNA P02545 1/20 0.84
HBB P68871 1/20 0.84
CYP1A2 P05177 1/20 0.84
CYP3A4 P08684 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Riboflavin SCHEMBL182060 1.00 MEN1 (0.84) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL27497064 0.99 MEN1 (0.82) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL5991517 0.95 MEN1 (0.89) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL5991520 0.95 MEN1 (0.89) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL6662783 0.95 MEN1 (0.75) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL27781309 0.95 MEN1 (0.81) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL27764351 0.95 MEN1 (0.81) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL2800233 0.94 MEN1 (0.89) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL2800236 0.94 MEN1 (0.89) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL27604024 0.93 MEN1 (0.78) MEN1KMT2AUSP2KDM4EHAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365850-B2 Water-miscible functional fluid, undiluted stock of water-miscible functional fluid, sterilizer for water-miscible functional fluid, and method of sterilizing water-miscible function fluid YUSHIRO CHEMICAL INDUSTRY CO., LTD. (JP) 2025-07-22 US claimed
CN-119185313-A Leishmod prodrug, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-12-27 CN claimed
WO-2024225436-A1 OPHTHALMIC COMPOSITION 株式会社メドレックス 2024-10-31 WO claimed
WO-2021261599-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR NOVEL CORONA VIRUS INFECTIOUS DISEASE 荒木 誠一 2021-12-30 WO claimed
CN-108135883-B Pharmaceutical composition containing arylalkylamine compound 协和麒麟株式会社 2021-09-14 CN claimed
US-10350194-B2 Pharmaceutical composition containing an arylalkylamine compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-16 US claimed
US-20180296526-A1 A PHARMACEUTICAL COMPOSITION CONTAINING AN ARYLALKYLAMINE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2018-10-18 US claimed
CN-108135883-A Pharmaceutical composition containing arylalkylamine compound 协和发酵麒麟株式会社 2018-06-08 CN claimed
EP-2050439-B1 PROCESS FOR PRODUCTION OF SPHERICAL GRANULE CONTAINING SLIGHTLY WATER-SOLUBLE SUBSTANCE ASAHI CHEMICAL IND (JP) 2016-11-23 EP claimed
US-20150343009-A1 ORALLY ADMINISTERED LIQUID FORMULATION TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-12-03 US claimed
CN-1489462-A Blood lipid ameliopant composition 三共株式会社 2004-04-14 CN claimed
CN-1489464-A Blood lipid improving agent composition 三共株式会社 2004-04-14 CN claimed
US-20040023919-A1 Blood lipid ameliorant composition SANKYO COMPANY, LIMITED (JP) 2004-02-05 US claimed
US-20040014712-A1 Blood lipid ameliorant composition SANKYO COMPANY, LIMITED (JP) 2004-01-22 US claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
EP-0328129-B1 Yellow-colored solid matter and production thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-08-17 EP claimed
EP-0553777-A2 Fast dissolving tablet and its production TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-08-04 EP claimed
EP-0328129-A2 Yellow-colored solid matter and production thereof Takeda Chemical Industries, Ltd. (JP) 1989-08-16 EP claimed
US-4612187-A Oryzanol-containing soft capsule NISSHIN CHEMICALS CO., LTD. (JP) 1986-09-16 US claimed
US-3962436-A Pharmaceutical compositions having controlled rate of gastro-intestinal absorption SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-06-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296526-A1 A PHARMACEUTICAL COMPOSITION CONTAINING AN ARYLALKYLAMINE COMPOUND NAT1, ABCB11, ADRA1A MEN1 2167/4885KMT2A 1428/4885USP2 4584/4885
US-10350194-B2 Pharmaceutical composition containing an arylalkylamine compound NAT1, ADRA1A, ADRA1B MEN1 2197/4885KMT2A 1311/4885USP2 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.